Patients with advanced bladder cancer benefit from anti-PD-L1 immunotherapy

Bookmark and Share
Published: 5 Jun 2016
Views: 1974
Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Dr Balar presents at ASCO 2016, results from a non-randomised phase II trial which showed that anti-PD-L1 immunotherapy atezolizumab is effective in patients with previously untreated advanced bladder cancer and not eligible for the standard treatment with cisplatin.

Read the news story for more.